'Phase iii study' diaporamas de présentation

Targeted Drug Development: Wrong Turns and Blind Alleys On The Road to Success

Targeted Drug Development: Wrong Turns and Blind Alleys On The Road to Success. Janet E. Dancey, MD Investigational Drug Branch Cancer Therapy Evaluation Program National Cancer Institute March 3, 2004.

585 views • 36 slides

Starting Therapy for Low Risk Myeloma

Starting Therapy for Low Risk Myeloma. Robert Z. Orlowski, Ph.D., M.D. Director, Myeloma Section Professor, Departments of Lymphoma/Myeloma & Experimental Therapeutics Principal Investigator, M. D. Anderson SPORE in Multiple Myeloma Chair, Southwest Oncology Group Myeloma Committee.

549 views • 34 slides

Targeted Therapy in Head & Neck Cancer Anti-EGFR Treatment

1.28k views • 24 slides

Clinical trials in breast cancer in Italy: the Gruppo Italiano Mammella (GIM)

539 views • 23 slides

Clinical trials in breast cancer in Italy: the Gruppo Italiano Mammella (GIM)

519 views • 23 slides

(Thanks to Amnon Bar-Ilan for the origin of most of the Slides)

IPAMS/WRAP Phase III Oil & Gas Emission Inventory Project & WRAP O&G Workgroup October 22, 2008 WESTAR O&G Conference Lee Gribovicz. (Thanks to Amnon Bar-Ilan for the origin of most of the Slides). Oil and Gas Production in the Rocky Mountains.

325 views • 23 slides

Clinical trials in breast cancer in Italy: the Gruppo Italiano Mammella (GIM)

236 views • 23 slides

Cancer Center Trials at St. Barnabas Medical Center

Cancer Center Trials at St. Barnabas Medical Center. Oncology clinical research at Saint Barnabas Medical Center (SBMC) is supported by a staff of three.

300 views • 19 slides

H. Riess,

Phase III Study: Gemcitabine and 5-FU (24h infusion) with Folinic acid (GFF) vs. Gemcitabine alone (GEM) in the Treatment of Advanced, Inoperable Pancreatic Cancer - CONKO*-002 -. H. Riess,

347 views • 18 slides

Phase III Trial of Pazopanib in Locally Advanced and/or Metastatic Renal Cell Carcinoma

Phase III Trial of Pazopanib in Locally Advanced and/or Metastatic Renal Cell Carcinoma. Sternberg CN et al. ASCO 2009; Abstract 5021. (Oral Presentation). Introduction. Pazopanib, an oral angiogenesis inhibitor, has high affinity for PDGFR and VEGFR 1, 2 and 3 and also targets C-kit

1k views • 17 slides

Overview of Colorectal Cancer, Recent Studies, and Trial Design

255 views • 15 slides

Uinta Basin Air Quality Study Kathleen Sgamma

Uinta Basin Air Quality Study Kathleen Sgamma. Topics Covered. Background Purpose Timelines Project Details WRAP Phase III Oil & Gas Emissions Inventory Summary. Background. The Uinta Basin is one of several basins in the Intermountain West experiencing increased oil and gas activity

260 views • 13 slides

Endometrial Committee

Endometrial Committee. David Scott Miller, M.D., F.A.C.O.G., F.A.C.S. Director and Dallas Foundation Chair in Gynecologic Oncology Professor of Obstetrics & Gynecology University of Texas Southwestern Medical Center Dallas, Texas, U.S.A. Resected Endometrial.

294 views • 12 slides

STUDY 303

STUDY 303. A Phase III, Randomized, Multi-Center, Open-Label, 12 to 14 Month Extension Study to Evaluate the Safety and Tolerability of Mesalamine Given Once Daily Vs. Twice Daily for the Maintenance of Ulcerative Colitis in Remission. Study 303: Objectives. Study design Patient disposition

448 views • 12 slides

Delarue R et al. Proc ASCO 2013;Abstract TPS8616; Proc ICML 2013;Abstract 564.

RoCHOP Study: A Phase III Randomized S tudy of CHOP Compared to R omidepsin -CHOP in Untreated P eripheral T -Cell Lymphoma. Delarue R et al. Proc ASCO 2013;Abstract TPS8616; Proc ICML 2013;Abstract 564. Background.

271 views • 8 slides

Finn RS et al. Proc SABCS 2012;Abstract S1-6.

Results of a Randomized Phase 2 Study of PD 0332991, a Cyclin?Dependent Kinase (CDK) 4/6 Inhibitor, in Combination with Letrozole vs Letrozole Alone for First?Line Treatment of ER+/HER2? Advanced Breast Cancer (BC). Finn RS et al. Proc SABCS 2012;Abstract S1-6. Background.

253 views • 8 slides

140 views • 1 slides

Introduction

Table 3. Table 2. Table 1. Maximum Grade Toxicity Cycle #1. Maximum Grade Toxicity All Cycles. Baseline Characteristics (n=41). Grade 1 Grade 2 Grade 3 Grade 4 Leukopenia 4 (9.8) 6 (14.6) 1 (2.4) 0 Neutropenia 3 (7.3) 3 (7.3) 2 (4.9) 1 (2.4) Anemia 20 (48.8) 5 (12.2) 3 (7.3) 0

146 views • 1 slides

Introduction

Table 3. Table 2. Table 1. Maximum Grade Toxicity Cycle #1. Maximum Grade Toxicity All Cycles. Baseline Characteristics (n=41). Grade 1 Grade 2 Grade 3 Grade 4 Leukopenia 4 (9.8) 6 (14.6) 1 (2.4) 0 Neutropenia 3 (7.3) 3 (7.3) 2 (4.9) 1 (2.4) Anemia 20 (48.8) 5 (12.2) 3 (7.3) 0

99 views • 1 slides